Despite positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable resistance from pharmacy benefit managers. The companies are https://ihannayxab497987.imblogs.net/91896658/copyright-s-medication-faces-is-meeting-pbm-obstacles-the-review-of-coverage-disputes